ATAD2 is overexpressed in a wide range of human cancers, including breast, lung, and prostate carcinomas, and it is present in low levels in normal non-tumour cells.3–5 The overexpression of ATAD2 has been associated with a poor patient outcome to treatment in breast,6 lung,7 ovarian,8 hepatocellular,9 endometrial10 and gastric11 cancers. Here, ATAD2 is linked to prostate carcinoma.